hematuria/tyrosine

Linkul este salvat în clipboard

ArticoleStudii cliniceBrevete

Alegeți tipul de sortare

12 rezultate

A rare case of synchronous renal cell carcinoma of the bladder presenting with gross hematuria.

Numai utilizatorii înregistrați pot traduce articole

A 57-year old man was referred to the Urology Department due to gross hematuria; abdominal ultrasound revealed an unspecific solid tumor of the left bladder wall. Ultrasound, transurethral resection of the bladder mass with subsequent histological analysis, thoracic and abdominal computed

Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers.

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE This phase I, first-in-human study evaluated the safety, tolerability, pharmacokinetics, and maximum-tolerated dose (MTD) of an oral platelet-derived growth factor receptor inhibitor, CP-868,596. METHODS Patients with advanced solid tumors were eligible. Dose escalations were performed in

Rapidly progressing renal cell carcinoma associated with Xp11.2 translocations: a case report.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND Renal cell carcinoma associated with Xp11.2 translocations is frequently reported in children, but adult-onset is rare. Here, the case of an adult male who developed a renal cell carcinoma associated with Xp11.2 translocations is presented. METHODS A 38-year-old Asian man presented with

Effects of Food on the Pharmacokinetic Properties of Surufatinib: A Phase I, Single-dose, Randomized, Open-label Crossover Study in Healthy Subjects

Numai utilizatorii înregistrați pot traduce articole

Purpose: Surufatinib is a potent and orally active small-molecule tyrosine kinase inhibitor targeting VEGFRs 1 to 3, FGFR-1, and CSF-1R, and thus may exert antitumor and antiangiogenic effects. The objective of this study was to determine

[Clinical recommendations for treating and monitoring patients with renal cancer].

Numai utilizatorii înregistrați pot traduce articole

Clear cell renal carcinoma is the most common kidney cancer. It is generally asymptomatic. A small percentage of patients present with hematuria, flank pain and abdominal mass. It is usually detected accidentally during radiologic examination. The diagnosis of kidney cancer is confirmed by

Concurrent occurrence of renal cell carcinoma with rhabdoid features in a married couple: a case report.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND Renal cell carcinoma (RCC) with rhabdoid features is a rare histology and exhibits clinically aggressive behavior. We report a case of a married couple in whom RCC with rhabdoid features concurrently occurred. The rarity of this event suggests that environmental factors may contribute to

Long-term survival following multidisciplinary treatment of metastatic sarcomatoid renal cell carcinoma: a case report.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND We report the case of a 62-year-old woman diagnosed with sarcomatoid renal cell carcinoma. METHODS A 62-year-old Asian woman presented with macroscopic hematuria. A histological and immunohistochemical study of a tumor biopsy specimen led to a suspected diagnosis of sarcomatoid renal cell

Anti-glomerular basement membrane glomerulonephritis following nintedanib for idiopathic pulmonary fibrosis: a case report.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND We report a previously unrecognized and unreported case of a patient with anti-glomerular basement membrane glomerulonephritis following nintedanib, an orally active small molecule tyrosine kinase inhibitor. METHODS A 59-year-old Caucasian woman with a history of idiopathic pulmonary

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.

Numai utilizatorii înregistrați pot traduce articole

Ibrutinib, an oral inhibitor of Bruton tyrosine kinase, is approved for patients with mantle cell lymphoma (MCL) who have received one prior therapy. We report the updated safety and efficacy results from the multicenter, open-label phase 2 registration trial of ibrutinib (median 26.7-month

Development of Focal Segmental Glomerulosclerosis and Thrombotic Microangiopathy in a Liver Transplant Patient on Sorafenib for Hepatocellular Carcinoma: A Case Report.

Numai utilizatorii înregistrați pot traduce articole

Transplant patients are at risk for hemodynamic injury and glomerular diseases such as focal segmental glomerulosclerosis (FSGS) and thrombotic microangiopathy (TMA). Calcineurin inhibitors (CNI) can cause various patterns of acute kidney injury (AKI) in transplant patients and their effects must be

Pharmacokinetics of vandetanib: three phase I studies in healthy subjects.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND Vandetanib is an orally available inhibitor of vascular endothelial growth factor receptor 2 and epidermal growth factor receptor and is rearranged during transfection tyrosine kinase activity. Development has included studies in non-small cell lung cancer and other tumor types. Accurate

Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.

Numai utilizatorii înregistrați pot traduce articole

Renal medullary carcinoma (RMC) is a rare kidney tumor that occurs in adolescent and young adults, typically in association with sickle cell trait. RMC exhibits rapid disease progression, frequent metastases at diagnosis, and dismal clinical outcomes. Currently available therapies, including

Alăturați-vă paginii
noastre de facebook

Herbal & Natural Medicine

Cea mai completă bază de date cu plante medicinale susținută de știință

Funcționează în 55 de limbi
Cure pe bază de plante susținute de știință
Recunoașterea ierburilor după imagine
Harta GPS interactivă - etichetați ierburile în locație (în curând)
Citiți publicațiile științifice legate de căutarea dvs.
Căutați plante medicinale după efectele lor
Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele

Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate